Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML.

× No keyword cloud information.

55 in total

1. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.

Authors: Chi Wai So; Michael L Cleary
Journal: Mol Cell Biol Date: 2002-09 Impact factor: 4.272

2. Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery.

Authors: Chun Guo; Qiande Hu; Chunxia Yan; Jinsong Zhang
Journal: Mol Cell Biol Date: 2009-03-16 Impact factor: 4.272

Review 3. Whole genome scanning as a cytogenetic tool in hematologic malignancies.

Authors: Jaroslaw P Maciejewski; Ghulam J Mufti
Journal: Blood Date: 2008-05-27 Impact factor: 22.113

Review 4. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches.

Authors: Megan A Hatlen; Lan Wang; Stephen D Nimer
Journal: Front Med Date: 2012-08-09 Impact factor: 4.592

5. The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain.

Authors: Michael J Plevin; Jinsong Zhang; Chun Guo; Robert G Roeder; Mitsuhiko Ikura
Journal: Proc Natl Acad Sci U S A Date: 2006-06-27 Impact factor: 11.205

Review 6. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors: Katrina J Falkenberg; Ricky W Johnstone
Journal: Nat Rev Drug Discov Date: 2014-08-18 Impact factor: 84.694

7. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia.

Authors: William E Pierceall; Steven M Kornblau; Nicole E Carlson; Xuelin Huang; Noel Blake; Ryan Lena; Michael Elashoff; Marina Konopleva; Michael H Cardone; Michael Andreeff
Journal: Mol Cancer Ther Date: 2013-10-03 Impact factor: 6.261

8. Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype.

Authors: Tadayuki Akagi; Seishi Ogawa; Martin Dugas; Norihiko Kawamata; Go Yamamoto; Yasuhito Nannya; Masashi Sanada; Carl W Miller; Amanda Yung; Susanne Schnittger; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
Journal: Haematologica Date: 2009-01-14 Impact factor: 9.941

9. MLL5 contributes to hematopoietic stem cell fitness and homeostasis.

Authors: Yan Zhang; Jasmine Wong; Mark Klinger; Mary T Tran; Kevin M Shannon; Nigel Killeen
Journal: Blood Date: 2008-09-25 Impact factor: 22.113

10. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

Authors: Luke F Peterson; Ming Yan; Dong-Er Zhang
Journal: Blood Date: 2007-02-06 Impact factor: 22.113